ICML 2023 | Differences between NLPHL and classical HL & promising treatment approaches for NLPHL
Michael Binkley
• 15 Jun 2023
Michael Binkley, MD, MS, Stanford University School of Medicine, Stanford, CA, discusses the differences between nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and classical HL (cHL), highlighting the need for a better understanding of these differences before individualized treatment approaches are possible. Dr Binkley then goes on to emphasize the importance of studying de-intensification treatment approaches for low-risk patients. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
